About US
Contact us
-
J&J eyes prostate cancer boost as FDA accepts Erleada for real-time reviewJohnson & Johnson has fallen behind the Pfizer-Astellas team with Erleada in the drug’s first approved indication. But now it looks poised to bring in another. The FDAacceptedthe New Jersey drugm2019/5/6
-
New Gilead chief plots Kite CEO hire, pipeline M&A and organizational tweaksGilead Sciences tapped new CEO Daniel O’Day in part because of his cancer expertise. But he’s not planning to lead the company’s oncology ramp-up alone. The Roche veteran intends to bring on a CEO fo2019/5/6
-
Endo CEO Campanelli nabs almost $20M in 2018 pay, thanks to special 2017 bonusEndo’s stock price hasn’t at all recovered from a sharp decline thanks to generics price erosion and a gloomy outlook for the company’s business. But CEO Paul Campanelli snagged a huge pay pump in 202019/5/5
-
Indivior slashes sales projections almost in half after $3B federal indictmentWith a $3 billion lawsuit from the U.S. government hanging overhead and Suboxone generics on the march, things are looking grim for Indivior. And executives warned Thursday that sales will take a big2019/5/5
-
Roche's Tecentriq-Avastin lung cancer combo gets a lift from England's cost watchdogsRoche has some hard-earned knowledge about working with England’s cost watchdogs, especially where its cancer drugs are concerned. And it put that know-how to use to score backing for Tecentriq in lu2019/4/30
-
GSK's Shingrix skyrockets toward the £1B mark as HIV drugs falterGlaxoSmithKline’s shingles vaccine Shingrix is growing insanely fast. So fast, in fact, it's on track to surpass £1 billion in sales for its second full year on the market. But another pillar of the2019/4/30
-
Eli Lilly aims to keep current Lartruvo patients as drug exits world stageEli Lilly'shigh hopes for Lartruvo hit the skids in January when the soft tissue sarcoma therapy flunked a phase 3 trial. Now that the failed drug is movingoff the market, Lilly's trying to keep curr2019/4/29
-
Say goodbye to AbbVie's ever-growing Humira sales: The biosim decline has officially begunAbbVie's Humira just posted its first-ever drop in worldwide sales—and with biosimilars on the march in Europe, it's not likely to be the last. Make no mistake; AbbVie is still making a fortune off t2019/4/29
-
As Roundup suits pile on, Bayer's drugs deliver a surprisingly good showIt’s no surprise that blood thinner Xarelto and vision drug Eylea drove Bayer’s pharma growth again this quarter—they have beenfor a long time. But cancer drugs Nexavar and Stivarga and hemophilia th2019/4/28
-
Bristol arms itself for kidney-cancer fight as Keytruda threatens Opdivo's shareBristol-Myers Squibb investors have been dreading the arrival of Merck’s Keytruda in kidney cancer, one of Opdivo’s key growth areas. Bristol’s execs? Not so much. The company has been preparing for2019/4/28